Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali

OBJECTIVES: To evaluate the virological response and to describe the resistance profiles in the case of failure after 6 months of first-line highly active antiretroviral therapy (HAART) in HIV-1-infected children living in resource-limited settings. PATIENTS AND METHODS: Ninety-seven HIV-1-infected children who started two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-nucleoside reverse transcriptase inhibitor (NNRTI) (mainly zidovudine/lamivudine/nevirapine) in Mali were prospectively studied. Virological failure (VF) was defined as loss to follow-up death or HIV-1 RNA viral load (VL) of >400 copies/mL at 6 months. When VL was >50 copies/mL a genotypic resistance test was performed. RESULTS: Among the 97 children median age at antiretroviral initiation was 31 months and the majority were in WHO clinical (77.3%) and immunological (70.1%) stage III or IV. At month 6 44% of children had VL > 400 copies/mL (61% VF). Among the children with detectable VL 30/37 genotypic resistance tests were available 8 with wild-type viruses and 22 with resistance mutations (73%): 19 M184V/I 21 NNRTI mutations and only 3 thymidine analogue mutations (TAMs) (K70R D67N and L210W in three distinct viruses). At failure 6/8 children with wild-type viruses had a VL of 1000 copies/mL. CONCLUSIONS: Under NNRTI-based regimens early detection of VF could allow the reinforcement of adherence when VL was 1000 copies/mL. The low frequency of TAMs suggests that most NRTIs can be used in a second-line regimen after early failure.